Abstract: A composition for the delayed delivery of a peptide active agent comprising; i) a salt of said peptide active agent comprising at least one positively charged peptide ion and at least one negatively charged counter-ion ii) a sustained-release delivery vehicle. Wherein said at least one negatively charged counter-ion is a halide ion, preferably a chloride or bromide ion.
Type:
Application
Filed:
June 13, 2008
Publication date:
August 19, 2010
Applicant:
CAMURUS AB
Inventors:
Markus Johnsson, Fredrik Joabsson, Catalin Nistor, Krister Thuresson, Fredrik Tiberg
Abstract: The present invention relates to compositions forming a low viscosity mixture of: a) at least one diacyl glycerol; b) at least one phosphatidyl choline; c) at least one oxygen containing organic solvent; d) at least one GnRH analogue; Wherein the pre-formulation forms, or is capable of forming, at least one liquid crystalline phase structure upon contact with an aqueous fluid. The invention further relates to methods of treatment comprising administration of such compositions, pre-filled administration devices and kits containing the formulations.
Type:
Application
Filed:
December 9, 2005
Publication date:
July 2, 2009
Applicant:
CAMURUS AB
Inventors:
Fredrik Joabsson, Markus Johnsson, Fredrik Tiberg
Abstract: The present invention relates to a particulate composition containing; a) 5 to 90% of at least one phosphatidyl choline component b) 5 to 90% of at least one diacyl glycerol component, at least one tocopherol, or mixtures thereof, and c) 1 to 40% of at least one non-ionic stabilising amphiphile, where all parts are by weight relative to the sum of the weights of a+b+c and where the composition contains particles of at least one non-lamellar phase structure or forms particles of at least one non-lamellar phase structure when contacted with an aqueous fluid. The invention additionally relates to pharmaceutical formulations containing such compositions, methods for their formation and methods of treatment comprising their administration.
Abstract: The present invention provides a particulate composition including; a) at least 50 % of at least one structure forming amphiphile, b) 0 to 40% of at least one structure swelling amphiphile, and c) 2 to 20% of at least one dispersion stabilising polymeric amphiphile, where all parts are by weight relative to the sum of the weights of a+b+c and wherein the composition comprises non-lamellar particles or forms non-lamellar particles when contacted with an aqueous fluid. Where component b) is 0% then component a) comprises at least two structure forming amphiphiles. The invention also provides pharmaceutical compositions of the compositions and kits containing the compositions for establishing a pharmaceutical formulation of an active agent.
Abstract: The present invention relates to compositions forming a low viscosity mixture of: a) at least one neutral diacyl lipid, such as a diacyl glycerol; b) at least one phospholipid, such as a phosphatidyl choline; c) at least one biotolerable solvent, such as an oxygen containing solvent; d) at least one GLP-1 analogue; wherein the pre-formulation forms, or is capable of forming, at least one liquid crystalline phase structure upon contact with an aqueous fluid. The invention further relates to methods of treatment comprising administration of such compositions, especially in treating diabetes, and to pre-filled administration devices and kits containing the formulations.
Type:
Application
Filed:
June 6, 2006
Publication date:
June 19, 2008
Applicant:
CAMURUS AB
Inventors:
Fredrik Joabsson, Markus Johnsson, Fredrik Tiberg
Abstract: The present invention relates to formulations of a lipid based controlled-release matrix, a polyhydroxy component and a bioactive agent. Such formulation are useful in the delivery of the bioactive compounds. The invention also relates to the use of a polyhydroxy component for increasing the solubility of a bioactive compound, especially a peptide in a lipid-based controlled-release matrix.
Type:
Application
Filed:
October 24, 2007
Publication date:
May 29, 2008
Applicant:
CAMURUS AB
Inventors:
Markus JOHNSSON, Fredrik TIBERG, Catalin NISTOR
Abstract: The present invention provides a method for forming a dispersion comprising non-lamellar amphiphile particles having improved phase behaviour, particle size distribution and/or storage stability, said method comprising forming a dispersion of lamellar and optionally non-lamellar particles comprising at least one structuring agent in a polar solvent, heating said particles to an elevated temperature, followed by cooling, wherein said heating is to a temperature and for a period sufficient to provide, after cooling, a measurable improvement in phase behaviour, particle size distribution and/or storage stability.
Type:
Application
Filed:
August 4, 2004
Publication date:
June 14, 2007
Applicant:
CAMURUS AB
Inventors:
Gert Worle, Frederik Tiberg, Markus Johnsson, Heike Bunjes, Britta Siekmann, Justas Barauskas
Abstract: The present invention provides a method for the production of amphiphile particles having incorporated therein at least one active agent. The method comprises forming a dispersion of particles comprising at least one amphiphilic structuring agent in a solution of at least one active agent, heating said dispersion to an elevated temperature, followed by cooling to around ambient temperature. The loading provided thereby is typically at least 130% of the loading provided by equilibration of the particles in a solution of active agent. The invention also provides corresponding amphiphile particles.
Type:
Application
Filed:
August 4, 2004
Publication date:
May 17, 2007
Applicant:
CAMURUS AB
Inventors:
Fredrik Joabsson, Fredrik Tiberg, Markus Johnsson
Abstract: The present invention provides an orally administrable composition comprising a dry mixture of polymer, lipid and bioactive agent, being capable on contact with water or GI tract liquid of forming particles comprising said lipid and said bioactive agent and optionally also water. It is preferable that such particles have a liquid crystalline phase structure. The invention also provides a method for the formation of compositions comprising polymer, lipid and bioactive agent.
Type:
Application
Filed:
March 12, 2004
Publication date:
April 6, 2006
Applicant:
CAMURUS AB
Inventors:
Helena Ljusberg-Wahren, Fredrik Joabsson, Krister Thuresson
Abstract: A saliva substitute, the characteristic feature of which is that it comprises water-soluble linseed polysaccharides. Said substitute is preferably in the form of an aqueous solution having a viscosity within the range of 1-30 mPa.s, most preferably 2-10 mPa.s. The substitute can be prepared by extracting the polysaccharides from linseed by means of water or a water solution containing inorganic salts. In addition to the fact that said substitute is useful as a saliva substitute it can also be utilized as a carrier for pharmaceuticals adapted for oral applications.
Type:
Grant
Filed:
April 6, 1992
Date of Patent:
November 9, 1993
Assignee:
Camurus AB
Inventors:
Rolf Attstrom, Per O. Glantz, Hakan Hakansson, Kare Larsson
Abstract: An article adapted for applications where there is contact with blood and especially in medical applications is prepared by adsorbing the enzyme, lysozyme or derivative thereof, onto a substrate and then adsorbing heparin or a heparin-based material to the enzyme. The substrate is preferably a metal or polymeric material.
Type:
Grant
Filed:
November 14, 1988
Date of Patent:
March 19, 1991
Assignee:
Camurus AB
Inventors:
Kare V. Larsson, Sven E. Bergentz, Bengt L. T. Lindblad